NUAK2 is a therapeutically tractable regulator of RNA splicing and tumor progression in neuroendocrine prostate cancer

Mehraj, U.; Maimekov, U.; Manzoor, S.; Cordova, E.; Patel, M.; Mancera-Ortiz, I. Y.; Howell, S.; Davis-Gilbert, Z. W.; Wang, M.-E.; Chen, M.; Park, J. W.; Wang, Y.; Armstrong, A. J.; Huang, J.; Drewry, D. H.; Mitrofanova, A.; Macias, E.

doi:10.1101/2025.11.12.687734

bioRxiv · 10.1101/2025.11.12.687734

NUAK2 is a therapeutically tractable regulator of RNA splicing and tumor progression in neuroendocrine prostate cancer

Mehraj, U.·Maimekov, U.·Manzoor, S.·Cordova, E.·Patel, M.·Mancera-Ortiz, I. Y.·Howell, S.·Davis-Gilbert, Z. W.·Wang, M.-E.·Chen, M.·Park, J. W.·Wang, Y.·Armstrong, A. J.·Huang, J.·Drewry, D. H.·Mitrofanova, A.·Macias, E.

View original source ↗Export metadata ↓

Abstract

Prostate cancer remains a leading cause of cancer-related mortality in men, with aggressive, treatment-emergent androgen receptor (AR)-indifferent subtypes, including double-negative prostate cancer (DNPC) and neuroendocrine prostate cancer (NEPC), posing major clinical challenges due to limited therapeutic options. NUAK family kinase 2 (NUAK2), an AMPK-related kinase, has been implicated in tumor growth and metastatic progression; however, its functional significance and therapeutic potential in advanced prostate cancer remain largely unexplored. Here, we identify NUAK2 as a therapeutically actionable kinase dependency in AR-indifferent prostate cancer. Transcriptomic analyses across independent patient cohorts demonstrated progressive upregulation of NUAK2 with disease progression, with the highest expression in NEPC. Immunohistochemical analysis of clinical specimens further confirmed elevated NUAK2 protein expression in NEPC relative to prostate adenocarcinoma. Genetic loss- and gain-of-function studies established NUAK2 as a functional dependency that promotes tumor cell proliferation, clonogenic growth, and tumor growth in vivo. Mechanistically, integrated proteomic analyses revealed that NUAK2 associates with spliceosomal and RNA-processing machinery, while NUAK2 perturbation induced widespread alterations in pre-mRNA splicing programs involving genes linked to mitotic regulation and oncogenic signaling. Pharmacologic studies identified trilaciclib (G1T-28), a clinically approved CDK4/6 inhibitor, as a functionally relevant NUAK2 inhibitor that directly engages NUAK2, suppresses tumor growth, and enhances the efficacy of platinum-based chemotherapy across multiple preclinical models. Collectively, these findings uncover NUAK2 as a previously unrecognized regulator of RNA splicing and therapeutic vulnerability in AR-indifferent prostate cancer and provide a rationale for repurposing G1T-28 and developing NUAK2-directed therapeutic strategies for aggressive, treatment-refractory prostate cancer.

Explore related subjects

cancer biology Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Mehraj, U., Maimekov, U., Manzoor, S., Cordova, E., Patel, M., Mancera-Ortiz, I. Y., Howell, S., Davis-Gilbert, Z. W., Wang, M.-E., Chen, M., Park, J. W., Wang, Y., Armstrong, A. J., Huang, J., Drewry, D. H., Mitrofanova, A., Macias, E.. 2025-11-13. NUAK2 is a therapeutically tractable regulator of RNA splicing and tumor progression in neuroendocrine prostate cancer. https://doi.org/10.1101/2025.11.12.687734

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Tet2-Clonal Hematopoiesis Promotes Whereas Dnmt3a-CH Inhibits Breast Cancer Progression During Aging

Clonal hematopoiesis of indeterminate potential (CHIP) driven by somatic mutations in blood cells increases with age and is associated with adverse outcomes in cancer patients. How CHIP mutations influence solid tumor progression remains unclear. Using inducible murine models of Dnmt3a- or Tet2-mutant CHIP combined with orthotopic syngeneic breast cancer models, we demonstrate that upon aging Dnmt3a-mutant CHIP prevents whereas Tet2-mutant CHIP drives breast cancer progression. Dnmt3a-mutant immune infiltrates established interferon-mediated MHCIIhigh tumor-associated macrophages (TAMs) that supported cytotoxic CD8+ T cell-mediated tumor rejection. In contrast, Tet2-mutant TAMs exhibited an inflammatory, immunosuppressive phenotype characterized by increased IL-1 and CXCL2 production, reduced MHCII expression, and impaired T cell recruitment and activation. Therapeutic blockade of IL-1R1 or CXCR2 reduced tumor progression in aged Tet2-mutant CHIP mice and partially restored anti-tumor immunity. These findings establish that the effects of CHIP on cancer are mutation- and age-dependent and identify IL-1/CXCL2-driven inflammation as a therapeutic vulnerability of tumor-promoting Tet2-mutant CHIP.

cancer biology↗

bioRxiv2026

Single Nucleus Profiling Reveals Rewired Tumor-Immune-Stromal Cell Communication in Plasmacytoid Urothelial Carcinoma

Plasmacytoid urothelial carcinoma (PUC) is an aggressive histologic subtype of bladder cancer associated with worse patient outcomes and therapeutic response compared to conventional urothelial carcinoma (CUC). While recent work has demonstrated metastatic lymph nodes from PUC tumors have an inflamed phenotype, how the tumor microenvironment (TME) and crosstalk between tumor, stromal, and immune cells in primary PUC bladder tumors differs from those in CUC remains poorly understood. The impact of these differences on response to immunotherapy is also unknown. To understand TME differences between CUC and PUC and their impact on cell signaling, we performed single nucleus RNA sequencing on PUC and CUC tumors, as well as Xenium spatial transcriptomics on a mixed CUC / PUC tumor. We identified increased signaling between PUC-enriched, CDH1-low urothelial cells, immunosuppressive lipid-associated macrophages, and SFRP2+/CTHRC1+ fibroblasts in PUC tumors compared to CUC. Spatial transcriptomics identified increased macrophage infiltration in PUC histology and colocalization of PUC tumor cells, immunosuppressive macrophages, and SFRP2+ fibroblasts. Taken together, this study delineates PUC architecture and demonstrates interplay CDH1-low tumor cells, EMT, and immunosuppressive macrophages, identifying possible therapeutic vulnerabilities in PUC.

cancer biology↗

bioRxiv2026

The Phospholipase A2 Activity of Peroxiredoxin 6 Protects Hepatocarcinoma Cells Against Ferroptosis and Mitophagy Impairment

Peroxiredoxin 6 (PRDX6) is a moonlighting protein that plays a key role in regulating redox homeostasis and lipid metabolism through its unique dual peroxidase and calcium-independent phospholipase A2 (iPLA2) activities. Here, we generated a stable HepG2 cell line harboring a D140A mutation to selectively ablate iPLA2 activity, and we compared its phenotype with that of wild-type (WT) and PRDX6-knockout (KO) cells. D140A exhibited low ROS leves, similar to WT cells, confirming that oxidative stress is due to peroxidase deficiency. In contrast, D140A cells displayed higher lipid peroxidation than WT cells, though significantly lower than that of KO cells. Furthermore, the D140A mutant mirrored the KO phenotype regarding intracellular ferrous iron accumulation, impaired lipid droplet biogenesis, and the downregulation of the key ferroptosis regulator GPX4. Mechanistically, integrated proteomic, lipidomic, and enzymatic analyses revealed that a deficiency in iPLA2 activity of PRDX6 disrupted the release of key lipid species necessary for cell structure and signaling. Consequently, organelles involved in lipid synthesis and trafficking, such as peroxisomes, endoplasmic reticulum, mitochondria and lipid droplet, were affected. Specifically, we found that mitochondria exhibited a reduction in cristae and a diminished capacity for mitophagy and autophagy, which ultimately makes cells much more susceptible to erastin-induced ferroptotic cell death. Taken together, our findings demonstrate that PRDX6 iPLA2 activity uniquely coordinates organelle lipid homeostasis and mitophagy to protect cancer cells from ferroptotic cell death. Consequently, the use of iPLA2 inhibitors such as MJ33, which decreased PRDX6 iPLA2 activity to a level comparable to the mutant D140A, could represent a promising therapeutic strategy for inducing ferroptotic cell death in hepatocellular carcinoma.

cancer biology↗